Fortrea Holdings (FTRE) Revenue (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Revenue came in at $678.2 million in Q2 2026, down 4.52% YoY from $710.3 million in Q2 2025, and up 6.55% on a QoQ basis from $636.5 million in Q1 2026.
Fortrea Holdings (FTRE) Revenue (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Revenue data on file, last reported at $678.2 million in Q2 2026.
- Quarterly Revenue fell 4.52% year-over-year to $678.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.7 billion (down 2.09% YoY) and the FY2025 annual result came in at $2.7 billion, up 1.0% from the prior year.
- Revenue rose to $678.2 million in Q2 2026, from $636.5 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $793.1 million in Q2 2022 to a low of $502.6 million in Q4 2022.
- A 5-year average of $684.4 million and a median of $693.9 million in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue surged 41.21% — and 2024, when it dropped 8.65%.
- Tracing FTRE's Revenue over 5 years: stood at $502.6 million in 2022, then surged by 41.21% to $709.7 million in 2023, then slipped by 1.79% to $697.0 million in 2024, then dropped by 5.24% to $660.5 million in 2025, then climbed by 2.68% to $678.2 million in 2026.
- The last three Revenue figures came in at $678.2 million (Q2 2026), $636.5 million (Q1 2026), and $660.5 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Fortrea Holdings | 1.66 Bn | 1.49 Bn | 139.20 Mn | 678.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 678.20 Mn |
| Mar 31, 2026 | 636.50 Mn |
| Dec 31, 2025 | 660.50 Mn |
| Sep 30, 2025 | 701.30 Mn |
| Jun 30, 2025 | 710.30 Mn |
| Mar 31, 2025 | 651.30 Mn |
| Dec 31, 2024 | 697.00 Mn |
| Sep 30, 2024 | 674.90 Mn |
| Jun 30, 2024 | 662.40 Mn |
| Mar 31, 2024 | 662.10 Mn |
| Dec 31, 2023 | 709.70 Mn |
| Sep 30, 2023 | 713.80 Mn |
| Jun 30, 2023 | 725.10 Mn |
| Mar 31, 2023 | 693.90 Mn |
| Dec 31, 2022 | 502.60 Mn |
| Sep 30, 2022 | 762.30 Mn |
| Jun 30, 2022 | 793.10 Mn |